Sign In
Buy KALV
$26.95
+0.0100 (+0.0371%)
At Close: Jun 03, 2026
KalVista Shares More Than Double on Drug Test Results
04:34pm, Tuesday, 09'th Feb 2021
Do favorable results in a mid-stage drug trial justify the stock of the developer more than doubling in a day?
KALV Stock: 8 Things to Know About KalVista Pharmaceuticals as Shares Skyrocket Today
11:14am, Tuesday, 09'th Feb 2021
Shares of KALV stock are blasting off on Tuesday after KalVista Pharmaceuticals reported strong results from its HAE treatment clinical trial. The post KALV Stock: 8 Things to Know About KalVista Phar
KalVista Surges 140% On Positive HAE Readout
10:44am, Tuesday, 09'th Feb 2021
Shares of Kalvista Pharmaceuticals Inc (NASDAQ: KALV) are sharply higher Tuesday following the release of a mid-Phase clinical readout. What Happened: Kalvista, which focuses on developing small mole
Investors Cheer Positive Data From KalVista's KVD900 Mid-Stage Hereditary Angioedema Trial
10:25am, Tuesday, 09'th Feb 2021
Kalvista Pharmaceuticals Inc's (NASDAQ: KALV) oral plasma kallikrein inhibitor, KVD900, has reduced the use of rescue medication in patients suffering swelling attacks associated with hereditary a
KALV Stock Price Increases Over 100% Pre-Market: Why It Happened
08:58am, Tuesday, 09'th Feb 2021
The stock price of Kalvista Pharmaceuticals Inc (NASDAQ: KALV) is trading at over 100% pre-market. This is why it happened.
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
07:00am, Thursday, 10'th Dec 2020
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm
Were Hedge Funds Right About Piling Into KalVista Pharmaceuticals, Inc. (KALV)?
01:24pm, Friday, 07'th Aug 2020
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that sm
KalVista Pharmaceuticals to Present at BTIG Virtual Biotechnology Conference
11:30am, Monday, 03'rd Aug 2020
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announc
KalVista Pharmaceuticals to Present at BTIG Virtual Biotechnology Conference
12:00am, Monday, 03'rd Aug 2020
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of
Geode Capital Management LLC Has $1.47 Million Holdings in Kalvista Pharmaceuticals Inc (NASDAQ:KALV)
04:22am, Friday, 17'th Jul 2020
Geode Capital Management LLC increased its position in shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) by 16.9% during the first quarter, according to its most recent Form 13F filing with the Sec
Outlook of Diabetic Macular Edema (DME) 2020-2025 - Current Landscape and the Way Forward - ResearchAndMarkets.com
12:00am, Monday, 13'th Jul 2020
The
Need To Know: Analysts Are Much More Bullish On KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Revenues
11:55am, Thursday, 02'nd Jul 2020
Celebrations may be in order for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) shareholders, with the analysts...
2020 Study into the Global Macular Edema Industry - Market Size and Drug Sales - ResearchAndMarkets.com
12:00am, Thursday, 02'nd Jul 2020
The
